68 related articles for article (PubMed ID: 34754233)
41. Short and mid-term outcomes of multimodal treatment for locally-advanced non-small cell lung cancer in elderly patients.
Bongiolatti S; Mazzoni F; Gonfiotti A; Di Pierro G; Salvicchi A; Borgianni S; Ferrari K; Voltolini L
Gen Thorac Cardiovasc Surg; 2020 Nov; 68(11):1290-1297. PubMed ID: 32419041
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
[TBL] [Abstract][Full Text] [Related]
43. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
44. Hypertension in older adults: Assessment, management, and challenges.
Oliveros E; Patel H; Kyung S; Fugar S; Goldberg A; Madan N; Williams KA
Clin Cardiol; 2020 Feb; 43(2):99-107. PubMed ID: 31825114
[TBL] [Abstract][Full Text] [Related]
45. Epidermal Growth Factor in Exhaled Breath Condensate as Diagnostic Method for Non-Small Cell Lung Cancer.
Chen J; Chen J; Lv X; Yang Q; Yao S
Technol Cancer Res Treat; 2019 Jan; 18():1533033819872271. PubMed ID: 31495334
[TBL] [Abstract][Full Text] [Related]
46. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
[TBL] [Abstract][Full Text] [Related]
47. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.
Miller TP; Fisher BT; Getz KD; Sack L; Razzaghi H; Seif AE; Bagatell R; Adamson PC; Aplenc R
Pediatr Blood Cancer; 2019 Jul; 66(7):e27747. PubMed ID: 30968531
[TBL] [Abstract][Full Text] [Related]
48. Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis.
Guo M; Li B; Yu Y; Wang S; Xu Y; Sun X; Wang L; Yu J
Cancer Med; 2019 May; 8(5):2587-2598. PubMed ID: 30945441
[TBL] [Abstract][Full Text] [Related]
49. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib.
Fang SC; Huang W; Zhang YM; Zhang HT; Xie WP
Onco Targets Ther; 2019; 12():985-992. PubMed ID: 30774384
[TBL] [Abstract][Full Text] [Related]
50. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer.
Bai ZG; Zhang ZT
Onco Targets Ther; 2018; 11():7077-7087. PubMed ID: 30410364
[TBL] [Abstract][Full Text] [Related]
51. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
52. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
53. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
54. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
Liu X; Qin S; Wang Z; Xu J; Xiong J; Bai Y; Wang Z; Yang Y; Sun G; Wang L; Zheng L; Xu N; Cheng Y; Guo W; Yu H; Liu T; Lagiou P; Li J
J Hematol Oncol; 2017 Sep; 10(1):153. PubMed ID: 28870253
[TBL] [Abstract][Full Text] [Related]
55. Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
Yang Y; Sun N; Sun P; Zhang L
Anticancer Res; 2017 Aug; 37(8):4681-4686. PubMed ID: 28739771
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and Risk Factors of Comorbidities among Hypertensive Patients in China.
Wang J; Ma JJ; Liu J; Zeng DD; Song C; Cao Z
Int J Med Sci; 2017; 14(3):201-212. PubMed ID: 28367080
[TBL] [Abstract][Full Text] [Related]
57. Antiangiogenic therapy in oncology: current status and future directions.
Jayson GC; Kerbel R; Ellis LM; Harris AL
Lancet; 2016 Jul; 388(10043):518-29. PubMed ID: 26853587
[TBL] [Abstract][Full Text] [Related]
58. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
59. A review of the management of elderly patients with non-small-cell lung cancer.
Blanco R; Maestu I; de la Torre MG; Cassinello A; Nuñez I
Ann Oncol; 2015 Mar; 26(3):451-63. PubMed ID: 25060421
[TBL] [Abstract][Full Text] [Related]
60. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study.
Li J; Chen P; Dai CH; Li XQ; Bao QL
Geriatr Gerontol Int; 2009 Jun; 9(2):172-82. PubMed ID: 19740361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
